Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Journal of Autism and Developmental Disorders 4/2014

01-04-2014 | Original Paper

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

Auteurs: Craig A. Erickson, Jeremy M. Veenstra-Vanderweele, Raun D. Melmed, James T. McCracken, Lawrence D. Ginsberg, Linmarie Sikich, Lawrence Scahill, Maryann Cherubini, Peter Zarevics, Karen Walton-Bowen, Randall L. Carpenter, Mark F. Bear, Paul P. Wang, Bryan H. King

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 4/2014

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.
Literatuur
go back to reference Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143–1154. PubMedCrossRef Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143–1154. PubMedCrossRef
go back to reference Baudouin, S. J., Gaudias, J., Gerharz, S., Hatstatt, L., Zhou, K., Punnakkal, P., et al. (2012). Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science, 338(6103), 128–132. PubMedCrossRef Baudouin, S. J., Gaudias, J., Gerharz, S., Hatstatt, L., Zhou, K., Punnakkal, P., et al. (2012). Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science, 338(6103), 128–132. PubMedCrossRef
go back to reference Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends Neuroscience, 27(7), 370–377. CrossRef Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends Neuroscience, 27(7), 370–377. CrossRef
go back to reference Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., et al. (2012). Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Science translational medicine, 4(152), 152ra127. Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., et al. (2012). Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Science translational medicine, 4(152), 152ra127.
go back to reference Centers for Disease Control. (2012). Prevalence of autism spectrum disorders–autism and developmental disabilities monitoring network, 14 sites, United States, 2008. Morbidity and mortality weekly report. Surveillance summaries, 61(3), 1–19. Centers for Disease Control. (2012). Prevalence of autism spectrum disorders–autism and developmental disabilities monitoring network, 14 sites, United States, 2008. Morbidity and mortality weekly report. Surveillance summaries, 61(3), 1–19.
go back to reference Fatemi, S. H., Folsom, T. D., Reutiman, T. J., & Thuras, P. D. (2009). Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum, 8(1), 64–69. PubMedCentralPubMedCrossRef Fatemi, S. H., Folsom, T. D., Reutiman, T. J., & Thuras, P. D. (2009). Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum, 8(1), 64–69. PubMedCentralPubMedCrossRef
go back to reference Gai, X., Xie, H. M., Perin, J. C., Takahashi, N., Murphy, K., Wenocur, A. S., et al. (2012). Rare structural variation of synapse and neurotransmission genes in autism. Molecular Psychiatry, 17(4), 402–411. PubMedCentralPubMedCrossRef Gai, X., Xie, H. M., Perin, J. C., Takahashi, N., Murphy, K., Wenocur, A. S., et al. (2012). Rare structural variation of synapse and neurotransmission genes in autism. Molecular Psychiatry, 17(4), 402–411. PubMedCentralPubMedCrossRef
go back to reference Gandal, M. J., Edgar, J. C., Ehrlichman, R. S., Mehta, M., Roberts, T. P., & Siegel, S. J. (2010). Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. Biological Psychiatry, 68(12), 1100–1106. PubMedCrossRef Gandal, M. J., Edgar, J. C., Ehrlichman, R. S., Mehta, M., Roberts, T. P., & Siegel, S. J. (2010). Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. Biological Psychiatry, 68(12), 1100–1106. PubMedCrossRef
go back to reference Hagerman, R., Hoem, G., & Hagerman, P. (2010). Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism, 1(1), 12. PubMedCentralPubMedCrossRef Hagerman, R., Hoem, G., & Hagerman, P. (2010). Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism, 1(1), 12. PubMedCentralPubMedCrossRef
go back to reference Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., et al. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Science translational medicine, 4(152), 152ra128. Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., et al. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Science translational medicine, 4(152), 152ra128.
go back to reference Huffman, L. C., Sutcliffe, T. L., Tanner, I. S., & Feldman, H. M. (2011). Management of symptoms in children with autism spectrum disorders: A comprehensive review of pharmacologic and complementary-alternative medicine treatments. Journal of Developmental and Behavioral Pediatrics, 32(1), 56–68. PubMedCrossRef Huffman, L. C., Sutcliffe, T. L., Tanner, I. S., & Feldman, H. M. (2011). Management of symptoms in children with autism spectrum disorders: A comprehensive review of pharmacologic and complementary-alternative medicine treatments. Journal of Developmental and Behavioral Pediatrics, 32(1), 56–68. PubMedCrossRef
go back to reference Jahromi, L. B., Kasari, C. L., McCracken, J. T., Lee, L. S., Aman, M. G., McDougle, C. J., et al. (2009). Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of Autism and Developmental Disorders, 39(3), 395–404. PubMedCrossRef Jahromi, L. B., Kasari, C. L., McCracken, J. T., Lee, L. S., Aman, M. G., McDougle, C. J., et al. (2009). Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of Autism and Developmental Disorders, 39(3), 395–404. PubMedCrossRef
go back to reference Kang, Y. H., Sun, B., Park, Y. S., Park, C. S., & Jin, Y. H. (2012). GABA(A) and GABA(B) receptors have opposite effects on synaptic glutamate release on the nucleus tractus solitarii neurons. Neuroscience, 209, 39–46. PubMedCrossRef Kang, Y. H., Sun, B., Park, Y. S., Park, C. S., & Jin, Y. H. (2012). GABA(A) and GABA(B) receptors have opposite effects on synaptic glutamate release on the nucleus tractus solitarii neurons. Neuroscience, 209, 39–46. PubMedCrossRef
go back to reference Kelleher, R. J., 3rd, Geigenmuller, U., Hovhannisyan, H., Trautman, E., Pinard, R., Rathmell, B., et al. (2012). High-throughput sequencing of mGluR signaling pathway genes reveals enrichment of rare variants in autism. PLoS One, 7(4), e35003. Kelleher, R. J., 3rd, Geigenmuller, U., Hovhannisyan, H., Trautman, E., Pinard, R., Rathmell, B., et al. (2012). High-throughput sequencing of mGluR signaling pathway genes reveals enrichment of rare variants in autism. PLoS One, 7(4), e35003.
go back to reference Krueger, D. D., & Bear, M. F. (2011). Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annual Review of Medicine, 62, 411–429. PubMedCentralPubMedCrossRef Krueger, D. D., & Bear, M. F. (2011). Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annual Review of Medicine, 62, 411–429. PubMedCentralPubMedCrossRef
go back to reference Kumar, R. A., & Christian, S. L. (2009). Genetics of autism spectrum disorders. Current neurology and neuroscience reports, 9(3), 188–197. PubMedCrossRef Kumar, R. A., & Christian, S. L. (2009). Genetics of autism spectrum disorders. Current neurology and neuroscience reports, 9(3), 188–197. PubMedCrossRef
go back to reference McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., et al. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127(5), e1312–e1321. PubMedCrossRef McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., et al. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127(5), e1312–e1321. PubMedCrossRef
go back to reference Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., et al. (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron, 74(1), 49–56. PubMedCrossRef Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., et al. (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron, 74(1), 49–56. PubMedCrossRef
go back to reference Oblak, A. L., Gibbs, T. T., & Blatt, G. J. (2010). Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. Journal of Neurochemistry, 114(5), 1414–1423. PubMedCentralPubMed Oblak, A. L., Gibbs, T. T., & Blatt, G. J. (2010). Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. Journal of Neurochemistry, 114(5), 1414–1423. PubMedCentralPubMed
go back to reference Paluszkiewicz, S. M., Martin, B. S., & Huntsman, M. M. (2011). Fragile X syndrome: The GABAergic system and circuit dysfunction. Developmental Neuroscience, 33(5), 349–364. PubMedCentralPubMedCrossRef Paluszkiewicz, S. M., Martin, B. S., & Huntsman, M. M. (2011). Fragile X syndrome: The GABAergic system and circuit dysfunction. Developmental Neuroscience, 33(5), 349–364. PubMedCentralPubMedCrossRef
go back to reference Posey, D., Erickson, C., Stigler, K., Diener, J., Kieffer, E., Kohn, A., et al. (2009). A double- blind, placebo- controlled trial of N- acetylcysteine in children with autism spectrum disorders. Paper presented at the American College of Neuropsychopharmacology, 48th annual meeting, Hollywood, FL. Posey, D., Erickson, C., Stigler, K., Diener, J., Kieffer, E., Kohn, A., et al. (2009). A double- blind, placebo- controlled trial of N- acetylcysteine in children with autism spectrum disorders. Paper presented at the American College of Neuropsychopharmacology, 48th annual meeting, Hollywood, FL.
go back to reference Posey, D. J., Erickson, C. A., McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child and adolescent psychiatric clinics of North America, 17(4), 787–801, viii–ix. Posey, D. J., Erickson, C. A., McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child and adolescent psychiatric clinics of North America, 17(4), 787–801, viii–ix.
go back to reference Rubenstein, J. L., & Merzenich, M. M. (2003). Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes Brain Behavior, 2(5), 255–267. CrossRef Rubenstein, J. L., & Merzenich, M. M. (2003). Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes Brain Behavior, 2(5), 255–267. CrossRef
go back to reference Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Dziura, J., et al. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589–598. PubMedCrossRef Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Dziura, J., et al. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589–598. PubMedCrossRef
go back to reference Scahill, L., Hallett, V., Aman, M. G., McDougle, C. J., Eugene Arnold, L., McCracken, J. T., et al. (2012). Brief report: Social disability in autism spectrum disorder: Results from research units on pediatric psychopharmacology (RUPP) autism network trials. Journal Autism Development Disorder, 43(3), 739–746. Scahill, L., Hallett, V., Aman, M. G., McDougle, C. J., Eugene Arnold, L., McCracken, J. T., et al. (2012). Brief report: Social disability in autism spectrum disorder: Results from research units on pediatric psychopharmacology (RUPP) autism network trials. Journal Autism Development Disorder, 43(3), 739–746.
go back to reference Silverman, J. L., Smith, D. G., Rizzo, S. J., Karras, M. N., Turner, S. M., Tolu, S. S., et al. (2012). Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Science translational medicine, 4(131), 131ra151. Silverman, J. L., Smith, D. G., Rizzo, S. J., Karras, M. N., Turner, S. M., Tolu, S. S., et al. (2012). Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Science translational medicine, 4(131), 131ra151.
go back to reference Skafidas, E., Testa, R., Zantomio, D., Chana, G., Everall, I. P., & Pantelis, C. (2012). Predicting the diagnosis of autism spectrum disorder using gene pathway analysis. Molecular Psychiatry. doi: 10.​1038/​mp.​2012.​126. Skafidas, E., Testa, R., Zantomio, D., Chana, G., Everall, I. P., & Pantelis, C. (2012). Predicting the diagnosis of autism spectrum disorder using gene pathway analysis. Molecular Psychiatry. doi: 10.​1038/​mp.​2012.​126.
go back to reference Watson, C., Hoeft, F., Garrett, A. S., Hall, S. S., & Reiss, A. L. (2008). Aberrant brain activation during gaze processing in boys with fragile X syndrome. Archives of General Psychiatry, 65(11), 1315–1323. PubMedCrossRef Watson, C., Hoeft, F., Garrett, A. S., Hall, S. S., & Reiss, A. L. (2008). Aberrant brain activation during gaze processing in boys with fragile X syndrome. Archives of General Psychiatry, 65(11), 1315–1323. PubMedCrossRef
go back to reference Yizhar, O., Fenno, L. E., Prigge, M., Schneider, F., Davidson, T. J., O’Shea, D. J., et al. (2011). Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature, 477(7363), 171–178. PubMedCrossRef Yizhar, O., Fenno, L. E., Prigge, M., Schneider, F., Davidson, T. J., O’Shea, D. J., et al. (2011). Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature, 477(7363), 171–178. PubMedCrossRef
Metagegevens
Titel
STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
Auteurs
Craig A. Erickson
Jeremy M. Veenstra-Vanderweele
Raun D. Melmed
James T. McCracken
Lawrence D. Ginsberg
Linmarie Sikich
Lawrence Scahill
Maryann Cherubini
Peter Zarevics
Karen Walton-Bowen
Randall L. Carpenter
Mark F. Bear
Paul P. Wang
Bryan H. King
Publicatiedatum
01-04-2014
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 4/2014
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-013-1963-z